Vauquelin Georges, Hall David, Charlton Steven J
Department Molecular and Biochemical Pharmacology, Vrije Universiteit Brussel, Brussels, Belgium.
Br J Pharmacol. 2015 May;172(9):2300-15. doi: 10.1111/bph.13053. Epub 2015 Mar 17.
Non-competitive drugs that confer allosteric modulation of orthosteric ligand binding are of increasing interest as therapeutic agents. Sought-after advantages include a ceiling level to drug effect and greater receptor-subtype selectivity. It is thus important to determine the mode of interaction of newly identified receptor ligands early in the drug discovery process and binding studies with labelled orthosteric ligands constitute a traditional approach for this. According to the general allosteric ternary complex model, allosteric ligands that exhibit negative cooperativity may generate distinctive 'competition' curves: they will not reach baseline levels and their nadir will increase in par with the orthosteric ligand concentration. This behaviour is often considered a key hallmark of allosteric interactions.
The present study is based on differential equation-based simulations.
The differential equation-based simulations revealed that the same 'competition binding' pattern was also obtained when a monovalent ligand binds to one of the target sites of a heterobivalent ligand, even if this process is exempt of allosteric interactions. This pattern was not strictly reciprocal when the binding of each of the ligands was recorded. The prominence of this phenomenon may vary from one heterobivalent ligand to another and we suggest that this phenomenon may take place with ligands that have been proposed to bind according to 'two-domain' and 'charnière' models.
The present findings indicate a familiar experimental situation where bivalency may give rise to observations that could inadvertently be interpreted as allosteric binding. Yet, both mechanisms could be differentiated based on alternative experiments and structural considerations.
作为治疗药物,能够对正构配体结合进行变构调节的非竞争性药物越来越受到关注。其备受追捧的优势包括药物效应的上限水平以及更高的受体亚型选择性。因此,在药物研发过程的早期确定新发现的受体配体的相互作用模式非常重要,而使用标记的正构配体进行结合研究是实现这一目标的传统方法。根据一般的变构三元复合物模型,表现出负协同性的变构配体可能会产生独特的“竞争”曲线:它们不会达到基线水平,且其最低点会随着正构配体浓度的增加而升高。这种行为通常被认为是变构相互作用的关键标志。
本研究基于基于微分方程的模拟。
基于微分方程的模拟显示,当单价配体与异二价配体的一个靶位点结合时,即使该过程不存在变构相互作用,也会获得相同的“竞争结合”模式。当记录每个配体的结合情况时,这种模式并非严格可逆。这种现象的显著程度在不同的异二价配体之间可能会有所不同,我们认为这种现象可能会发生在那些根据“双结构域”和“铰链”模型被认为能够结合的配体上。
本研究结果表明,在常见的实验情况下,二价性可能会导致一些观察结果被不经意地解释为变构结合。然而,这两种机制可以通过其他实验和结构方面的考虑加以区分。